Gala vs MEDVi: Which GLP-1 Provider Is Better?

By Iacob Pastina, Independent Researcher

53 providers verified independently·Independent research·How we rank →

Visit MEDVi - our pick of these two→or find your match

MEDVi beats Gala overall, scoring 7.7/10 vs 7.2/10. Gala is more affordable at $149/mo vs $179/mo. Choose Gala for tirzepatide-first patients who want a low-cost compounded pa. Choose MEDVi for users who want a low entry price with oral and injectable co.

A side-by-side look at Gala and MEDVi to help you decide. We compare them on:

•Starting price per month
•Our overall score, out of 10
•Medication type, brand-name or compounded
•Whether they accept insurance
•Who each one is best for

Gala

#39 of 53

7.2/10

Telehealth platform focused on compounded tirzepatide, both microdose and full-dose tiers, alongside a brand-name semaglutide (Ozempic) path and a 'coming soon' Wegovy pill. Operated by AI Coaching, Inc. (Wilmington, DE), backed by OpenLoop-affiliated medical groups (a recognized US telehealth backend) and LegitScript verified. Differentiator: a dedicated 'Gala GLP-1 Tracker' iOS + Android app for in-treatment dosing, weight, and side-effect logging.

Visit Gala

Higher Rated

MEDVi

#20 of 53

7.7/10

MEDVi is a compounded GLP-1 telehealth platform offering both oral tablets and injectable semaglutide and tirzepatide, with micro-dosing options for side-effect-sensitive patients. $179/mo entry pricing, free shipping, and a streamlined intake, one of the broader compounded mixes among independent telehealth providers in 2026.

Visit MEDVi

Feature	Gala	MEDVi
Our Score	7.2/10	7.7/10
Starting Price	$149/mo	$179/mo
Medication Type	Both	Both
Insurance Accepted	No	No
Best For	Tirzepatide-first patients who want a low-cost compounded path (microdose $149/mo or full-dose $179-199/mo) plus a dedicated iOS + Android tracker app for daily progress logging	Users who want a low entry price with oral and injectable compounded options
Watch out for	Brand-name Ozempic here is $1,299/mo, materially above market (NovoCare direct pricing for Wegovy is $349/mo; Hers offers Wegovy at $149/mo via the 2026 Novo Nordisk partnership). Buy brand-name elsewhere, Gala's value is its compounded tirzepatide.	No brand-name Wegovy or Zepbound on the platform (the 2026 expansion added branded Ozempic only)
Ranking	#39	#20
Get started	Visit Gala	Visit MEDVi

Pros & Cons Compared

Gala

Pros

+Microdose compounded tirzepatide at $149/mo, the cheapest microdose tirz on a tracked telehealth platform; full-dose compounded tirzepatide at $179/mo (yearly plan) or $199/mo (3-month plan)
+Dedicated 'Gala GLP-1 Tracker' on BOTH iOS and Android, first-party in-treatment logging is uncommon among compounded-only platforms
+OpenLoop-affiliated medical groups + LegitScript verification provide third-party accountability that many compounded-only platforms lack
+All 50 states, free shipping, no insurance required, 24/7 patient support claimed

Cons

−Brand-name Ozempic here is $1,299/mo, materially above market (NovoCare direct pricing for Wegovy is $349/mo; Hers offers Wegovy at $149/mo via the 2026 Novo Nordisk partnership). Buy brand-name elsewhere, Gala's value is its compounded tirzepatide.
−Tirzepatide-only on the compounded side, compounded semaglutide is NOT offered, a narrower medication menu than peers like Maximus, Ro, or Henry Meds
−Mixed Trustpilot reviews mention dosing inconsistencies and slow customer service responsiveness, verify your specific dose and batch with each refill
−Initial consultation is typically a sync video visit, but ongoing follow-ups are chat-based (no scheduled ongoing video access), and there are no published labs, no named medical director, no specialty obesity oversight
−Restrictive refund policy, Gala's published terms state 'IN NO EVENT SHALL YOU BE ISSUED A REFUND UPON CANCELLATION OF THE SUBSCRIPTION SERVICES' with a narrow exception for provider-initiated medical disqualification. No money-back guarantee. Read the published policy at galaglp1.com/refund-policy before enrolling on a commitment plan
−Newer brand under AI Coaching, Inc. (founded 2024 per LinkedIn), limited public company history; founders, founding year, and named medical director not publicly disclosed on galaglp1.com itself

MEDVi

Pros

+One of the few compounded providers offering both oral tablets and injectable semaglutide
+Micro-dosing options available, can start at sub-standard doses for patients concerned about side effects
+Sleek onboarding experience with clear progress tracking through their patient portal
+$179/mo is competitive for a platform with both oral and injectable compounded formulations

Cons

−No brand-name Wegovy or Zepbound on the platform (the 2026 expansion added branded Ozempic only)
−No insurance accepted, and oral compounded semaglutide has less clinical data than injectable forms; you can switch to injectable anytime at no extra fee if results lag

Our Verdict

MEDVi edges out Gala with a score of 7.7/10 vs 7.2/10. If budget is your priority, Gala starts at $149/mo compared to MEDVi's $179/mo. Choose Gala if you want: tirzepatide-first patients who want a low-cost compounded path (microdose $149/mo or full-dose $179-199/mo) plus a dedicated ios + android tracker app for daily progress logging. Choose MEDVi if you want: users who want a low entry price with oral and injectable compounded options.

Still undecided? Editor's Featured Pick

TrimRx

$149/mo · 7.8/10 · Compounded

If neither Gala nor MEDVi feels like the right fit, our featured pick across all 53 GLP-1 telehealth providers is TrimRx. It is not the highest-scored provider in our full rankings. We feature it for its low-friction value: a flat $149/mo that stays the same at every dose.

Visit TrimRx→Read our full TrimRx review